肌层浸润性膀胱癌保留膀胱三联治疗长期结局与失败模式
该单中心前瞻性分析纳入三种连续保留膀胱方案(最大程度经尿道膀胱肿瘤电切术联合放疗及顺铂为基础化疗)治疗肌层浸润性膀胱癌患者,报告10年膀胱保留率79%,10年总生存率43.2%、癌症特异生存率76.3%、无转移生存率79.2%,三种方案间总生存无统计学显著差异。
要点
- 10年膀胱保留率79%,10年OS 43.2%、CSS 76.3%、MFS 79.2%。
- 最大程度TURBT与诱导治疗后完全缓解是OS和MFS的独立相关因素。
- 浸润性膀胱复发独立关联更差CSS和MFS。
核心结论
- 10年结果提示保留膀胱治疗对经选择的肌层浸润性膀胱癌患者是成功策略。
- 最大程度TURBT和诱导治疗后完全缓解仍是最相关预测因素。
研究设计与样本
- 单中心前瞻性分析三种连续保留膀胱方案,联合最大程度TURBT、放疗和顺铂为基础化疗。
- 方案1为新辅助甲氨蝶呤-顺铂-长春碱后内镜再评估,完全缓解者接受巩固放疗60 Gy。
- 方案2为改变分割放疗64.8 Gy联合同期每周顺铂,40.8 Gy后再评估。
- 方案3为放疗64.8 Gy联合同期每周顺铂;无应答者行根治性膀胱切除术。
主要发现
- 10年膀胱保留率为79%。
- 10年OS、CSS和MFS分别为43.2%、76.3%和79.2%。
- 不同治疗方案间OS无统计学显著差异。
- 多因素分析中,最大程度TURBT和诱导治疗后完全缓解是改善OS和MFS的独立相关因素。
- 发生浸润性膀胱复发独立关联更差CSS和MFS。
临床怎么用
- 对经选择的肌层浸润性膀胱癌患者,保留膀胱三联治疗可作为长期管理策略。
- 最大程度TURBT和诱导治疗后完全缓解是预测长期生存的重要指标。
- 需监测浸润性膀胱复发,因其与更差CSS和MFS独立相关。
局限性
- 单中心前瞻性分析,非随机对照比较三种方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report long-term results on survival, toxicity, and patterns of failure of 3 different organ-sparing strategies for patients with muscle invasive bladder cancer. MATERIALS AND METHODS: This is a monoinstitutional prospective analysis of 3 consecutive bladder-sparing protocols combining maximal transurethral resection of bladder tumor (mTURBT), radiotherapy (RT), and cisplatin-based chemotherapy. Protocol 1 consisted of neoadjuvant methotrexate-cisplatin-vinblastine followed by endoscopic re-evaluation and consolidative RT 60 Gy in complete responders. Protocol 2 involved altered-fractionation RT 64.8 Gy and concurrent weekly cisplatin with re-evaluation after 40.8 Gy. Protocol 3 consisted of RT 64.8 Gy with concomitant weekly cisplatin. Nonresponders underwent radical cystectomy. Probabilities for overall survival (OS), cancer-specific survival (CSS), and metastasis-free survival (MFS) were calculated using Kaplan-Meier product limited estimates. A Cox regression multivariate analysis was performed to detect potential risk factors for OS, CSS, and MFS. RESULTS: The 10-year bladder preservation rate was 79%. The 10-year OS, CSS, and MFS rates were 43.2%, 76.3% and 79.2%, respectively. There was no statistically significant difference in OS between the different treatment protocols. On multivariate analysis, mTURBT of the bladder and the complete response after induction therapy were independent correlates of improved OS and of MFS. The development of invasive bladder recurrence was independently associated with worse CSS and MFS. CONCLUSION: Ten-year results indicate that bladder-sparing treatment is a successful approach for muscle invasive bladder cancer in selected patients. The mTURBT of the bladder tumor and complete response after induction therapy remain the most relevant predictive factors.
引用
- Büchser D, Zapatero A, Rogado J, et al. Long-term Outcomes and Patterns of Failure Following Trimodality Treatment With Bladder Preservation for Invasive Bladder Cancer. Urology. 2018. PMID: 30266376. doi:10.1016/j.urology.2018.07.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。